

# A Bayesian Model to Predict COVID-19 Severity in Children

Sara Domínguez-Rodríguez, MSc, \*†‡ Serena Villaverde, MD, \*†‡

Francisco J. Sanz-Santaefemia, MD, MSc, § Carlos Grasa, MD, †¶ Antoni Soriano-Arandes, PhD, ||

Jesús Saavedra-Lozano, PhD, \*\* Victoria Fumadó, MD, PhD, †† Cristina Epalza, MD, \*†‡

Miquel Serna-Pascual, MSc, \*†‡ José A. Alonso-Cadenas, MD, § Paula Rodríguez-Molino, MD, †¶

Joan Pujol-Morro, MD, || David Aguilera-Alonso, MD, \*\* Silvia Simó, MD, ††

Sara Villanueva-Medina, MD, \*†‡ M. Isabel Iglesias-Bouzas, MD, ‡‡ M. José Mellado, MD, PhD, §

Blanca Herrero, MD, PhD, § Susana Melendo, PhD, || Mercedes De la Torre, MD, §

Teresa Del Rosal, MD, PhD, †¶ Pere Soler-Palacin, MD, PhD, || Cristina Calvo, MD, PhD, §

María Urretavizcaya-Martínez, MD, §§ Marta Pareja, MD, ¶¶ Fátima Ara-Montojo, MD, ||||

Yolanda Ruiz del Prado, MD, \*\*\* Nerea Gallego, MD, ††† Marta Illán Ramos, MD, ‡‡‡ Elena Cobos, PhD, \*†‡

Alfredo Tagarro, PhD, \*†‡§§§ and Cinta Moraleda, MD, \*†‡ on behalf of EPICO-AEP Working Group

**Background:** We aimed to identify risk factors causing critical disease in hospitalized children with COVID-19 and to build a predictive model to anticipate the probability of need for critical care.

**Methods:** We conducted a multicenter, prospective study of children with SARS-CoV-2 infection in 52 Spanish hospitals. The primary outcome was the need for critical care. We used a multivariable Bayesian model to estimate the probability of needing critical care.

**Results:** The study enrolled 350 children from March 12, 2020, to July

Accepted for publication April 22, 2021

From the \*Fundación de Investigación Biomédica Hospital 12 de Octubre, Instituto de Investigación 12 de Octubre (imas12), Madrid, Spain; †RITIP (Translational Research Network in Paediatric Infectious Diseases), Madrid, Spain; ‡Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario 12 Octubre, Madrid, Spain; §Hospital Universitario Niño Jesús, Madrid, Spain; ¶Paediatrics, Infectious and Tropical Diseases Department, Hospital Universitario La Paz, Instituto Investigación Hospital La Paz (IDIPaz), Madrid, Spain; ||Paediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Catalonia, Spain; \*\*Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario Gregorio Marañón, Madrid, Spain; ††Paediatric Infectious Diseases Unit, Department of Paediatrics, Hospital Universitario Sant Joan de Deu Barcelona, Barcelona, Spain; ‡‡Paediatric Intensive Care Unit, Hospital Universitario Niño Jesús, Madrid, Spain; §§Paediatrics Department, Complejo Hospitalario de Navarra, Pamplona, Spain; ¶¶Paediatrics Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain; ||||Paediatrics Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain; \*\*\*Paediatrics Department, Hospital San Pedro, Logroño, Spain; †††Paediatrics Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain; ‡‡‡Paediatrics Department, Hospital Universitario Clínico San Carlos, Madrid, Spain; and §§§Paediatrics Department, Hospital Universitario Infanta Sofía, Paediatrics Research Group, Universidad Europea de Madrid, Madrid, Spain.

This work was supported by a specific Research Project of the Spanish Society of Paediatrics (Asociación Española de Pediatría). The study was funded by project PI20/00095, from the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) and cofunded by the European Regional Development Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. S.V. is funded by the Spanish Ministry of Science and Innovation—Instituto de Salud Carlos III and Fondos FEDER (Contrato Río Hortega CM20/00173).

The authors have no conflicts of interest to disclose. A.T. and C.M. contributed equally to this work.

Address for correspondence: Alfredo Tagarro, PhD, Servicio de Pediatría, Hospital Infanta Sofía de San Sebastián de los Reyes, 28703 Madrid, Spain. E-mail: alfredotagarro@gmail.com.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pidj.com)

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.  
ISSN: 0891-3668/21/4008-e287

DOI: 10.1097/INF.0000000000003204

1, 2020: 292 (83.4%) and 214 (73.7%) were considered to have relevant COVID-19, of whom 24.2% required critical care. Four major clinical syndromes of decreasing severity were identified: multi-inflammatory syndrome (MIS-C) (17.3%), bronchopulmonary (51.4%), gastrointestinal (11.6%), and mild syndrome (19.6%). Main risk factors were high C-reactive protein and creatinine concentration, lymphopenia, low platelets, anemia, tachycardia, age, neutrophilia, leukocytosis, and low oxygen saturation. These risk factors increased the risk of critical disease depending on the syndrome: the more severe the syndrome, the more risk the factors conferred. Based on our findings, we developed an online risk prediction tool (<https://rserver.h12o.es/pediatrica/EPICOAPP/>, username: user, password: 0000).

**Conclusions:** Risk factors for severe COVID-19 include inflammation, cytopenia, age, comorbidities, and organ dysfunction. The more severe the syndrome, the more the risk factor increases the risk of critical illness. Risk of severe disease can be predicted with a Bayesian model.

**Key Words:** COVID-19, SARS-CoV-2, children, syndrome, Bayesian

(*Pediatr Infect Dis J* 2021;40:e287–e293)

Recent data suggest that children are less susceptible to SARS-CoV-2 infection than adults, and their symptoms are usually milder.<sup>1–10</sup> However, it remains unclear how to identify early the patients that will have a severe disease. The heterogeneity of clinical presentation suggests that risk factors may vary depending on syndromic presentation.

There is a need to find potential predictors of severity in pediatric COVID-19 cases to stratify which patients may benefit from treatments. No models exist to predict severe disease for children with COVID-19.

This study aimed to identify risk factors associated with severe COVID-19 and to build a predictive model to anticipate the probability of need for critical care.

## METHODS

### Design

The Epidemiological Study of coronavirus in Children (EPICO-AEP) is a multicenter cohort study conducted in Spain to assess the characteristics of children with COVID-19. In total, 52 hospitals collected data from the beginning of the epidemic in Spain—February 25—until this analysis. The study was approved

by the Ethics Committee of the Hospital 12 de Octubre, Madrid (code 20/101), and other participating hospitals. Participants were enrolled after signed or verbal consent from parents/guardians and by the consent of patients older than 12 years.

Eligible participants were children 0–18 years of age attended in any of the hospitals of the network from March 12, 2020, to July 1, 2020, with a SARS-CoV-2 infection confirmed by real-time polymerase chain reaction (RT-PCR) or children fulfilling WHO criteria for MIS-C.<sup>11</sup>

## Laboratory Methods

Respiratory samples were obtained from nasopharyngeal swabs and tracheal or bronchial aspirates when available. Serum samples were analyzed in local clinical microbiology laboratories using commercial kits.

## Definitions

For analysis purposes, diagnoses were categorized into 4 syndromes: “MIS-C,” “bronchopulmonary syndrome” (including pneumonia, bronchiolitis, bronchitis, and asthma flare), “gastrointestinal syndrome” (including gastroenteritis and abdominal pain), and “mild syndrome” (including FWS, URTI, flu-like syndrome, and asymptomatic patients).

The primary outcome was need for critical care, defined as the combined outcome of admission into a pediatric intensive care unit, and need for respiratory support with high-flow oxygen, continuous positive airway pressure or mechanical ventilation.

To differentiate patients admitted for COVID-19 from those admitted for other reason but with mild/asymptomatic community-acquired or nosocomial SARS-CoV-2 infection, the term “relevant COVID-19 disease” (r-COVID-19) was created. This was defined as admission due to bronchopulmonary syndrome, MIS-C, gastrointestinal syndrome, or mild syndrome with an associated diagnosis that might be considered a complication of COVID-19 and conditioned hospitalization—for example, febrile seizures.

## Data Management and Statistical Analyses

Researchers from each participating hospital collected pseudo-anonymized data using a standardized clinical research form on the electronic data capture system REDCap.<sup>13</sup>

Statistical analyses were performed using the R language. Continuous variables including heart rate, respiratory rate, and blood pressure were categorized according to normal values for age.<sup>14</sup> To dichotomize the continuous variables without a standardized categorization, such as platelets and oxygen saturation (SatO<sub>2</sub>), optimal cutoff points were assessed using generalized additive models implemented in the `cutpointr` R package.<sup>15</sup> Each optimal cutoff point was specified in the descriptive tables and analysis.

For univariable analysis, the posterior probability of a positive correlation was calculated for summary tables using Bayesian univariable logistic regression.

To build a classification model that predicts the probability for critical care, a Naïve Bayes algorithm was made and implemented in a web app. All the variables with more than 80% probability of conferring risk in the univariable model and with <15% of missing values were included. Symptoms and signs that define syndromes (for instance, conjunctivitis, shock) were excluded as possible predictors because they were already included in the syndromes’ definitions (eg, MIS-C). All the included participants were randomly divided into a training dataset that was used to generate the models (70% of the original dataset), and a validation dataset used to assess the performance of the models (remaining 30%). Partitions were balanced by the outcome class, which yielded a training set (n = 151) and

a validation set (n = 63). All missing values were imputed independently for both datasets.

The algorithm was trained using 5-fold cross-validation as a resampling control method to prevent overfitting. Due to the disparity in the frequencies of the observed classes, ROSE down-sampling hybrid method was used. The variable importance was calculated to determine the predictors that significantly affect the algorithm classification output. A confusion matrix was built for each of the models to assess their accuracy, sensitivity, and specificity. The area under the curve of the receiver operating characteristic curves was determined for each model.

To estimate the increased probability of needing critical care according to the syndrome for each risk factor, Bayesian multivariable models were employed. Different models were employed including each risk factor, previously identified as important in the prediction Naïve Bayes model, and the syndrome. Probabilities for each condition were plotted according to each condition using the `ggplot2` package.<sup>16</sup>

For Bayesian analyses, Student’s *t* distribution with mean zero and 7 degrees of freedom was used as the weakly informative prior. All models were run with 4 Markov chains for 1000 warm-up and 100,000 sampling iterations. All models were programmed using the `stan_glm` function of R `rstanarm` package.<sup>17</sup>

## RESULTS

### Features of the Cohort

A total of 350 children were enrolled (Figure 1). The median age was 5.5 years (interquartile range [IQR], 0.55–12.1), 129/350 (36.9%) were ≤2 years old and 191/350 (54.6%) were male.

### Features of Patients With r-COVID-19

A total of 214 (73.7% of 292 hospitalized) patients were considered to have r-COVID-19.

Of the 214 participants with r-COVID-19, 93/214 (45.1%) had comorbidities. Regarding major clinical syndromes, 110/214 (51.4%) had bronchopulmonary syndrome (100/214 [46.7%] pneumonia), 42/214 (19.6%) had mild syndrome, 37/214 (17.3%) MIS-C and 25/214 (11.6%) gastrointestinal syndrome.

Of the 214 patients with r-COVID-19, 52 (24.2%) required critical care during a median of 5 (IQR 3.0–8.0) days.

Clinical characteristics of patients with r-COVID-19 who needed critical care are summarized in Table, Supplemental Digital Content 1, <http://links.lww.com/INF/E403>. The symptoms and other features most likely to be associated with requiring critical care in the univariable model are displayed in Figure 2 and Table, Supplemental Digital Content 1, <http://links.lww.com/INF/E403>.

### Critical Care Predictive Model

To build a comprehensive predictive model, a Naïve Bayes algorithm was trained and validated to predict critical care necessity. The predictors with higher relative importance to predict the necessity of critical care were high CRP, lymphopenia, platelets below 220,000/mm<sup>3</sup>, anemia, tachycardia, age, neutrophilia, leukocytosis, high creatinine, low oxygen saturation, fever, days of fever, high weight percentile, MIS-C, comorbidities, gastrointestinal syndrome, and bronchopulmonary syndrome. In the external validation, overall accuracy for the naïve Bayes classifier was 84% (95% confidence interval [CI]: 72.7–92.1). The model could predict the need for critical care with 80% (95% CI: 53–95.67) sensitivity and 85.4% (95% CI: 72.2–93) specificity; the positive predictive value was estimated as 63.2% (95% CI: 45.2–78.1) and the negative predictive value was 93.2% (95% CI: 83.15–97.4). The area under the curve was 76.6% (95% CI: 70.3–80.9).




FIGURE 1. Flowchart of the enrollment process of the study cohort.

In the validation set (n = 63), we compared the probability of critical care attributed by the model with the population of patients who actually needed and did not need critical care (Figure 3). There was a significant difference in the distribution of both groups, revealing the high classification ability. This model was implemented in the app (<https://rserver.h12o.es/EPICOAPP/>, Username: user, password: 0000).


### Differences in the Effect of Risk Factors According to Syndrome

Patients diagnosed with MIS-C (density plot, Figure 4, greenish color) had the highest probability of needing critical care, followed by bronchopulmonary syndrome (bluish) and


gastrointestinal syndrome (yellowish) as compared with mild syndrome. The different risk factors had different effects across the 4 syndromes.

The principal risk factors for critical care in patients with MIS-C were platelets <220,000/mm<sup>3</sup> (31%), presence of comorbidities (26%) and lymphopenia (25%). In patients with bronchopulmonary syndrome, the 3 most important risk factors were the same; however, these factors conferred less risk than in MIS-C: 24%, 20%, and 19%, respectively. Likewise, the 3 factors conferred some risk for gastrointestinal patients (10% each) but less than in MIS-C and bronchopulmonary syndrome.


Specifically, low platelets conferred 7% more risk of critical care in the MIS-C group than in the bronchopulmonary syndrome



**FIGURE 2.** Clinical features of the patients at presentation and probability of being associated with needing critical care. The posterior probability of  $\beta > 0$ , that is, the probability of each feature to have a positive correlation with critical care, is displayed (from 0 to 1).



**FIGURE 3.** Naïve Bayes predictor selection and model performance. The model was built with a set of 70% of patients and validated with a set of 30% of patients. (A) represents the relative variable importance from all the predictors included in the model. B: The patients included in the validation set ( $n = 63$ ) are displayed. The Y axis represents the distribution of the predicted probability for critical care given by the model. In the X axis, patients are separated according to their actual necessity of critical care. The probability of critical care attributed by the model was significantly different ( $P = 0.000002$ ) in the population of patients who actually needed and in the population that did not need critical care, showing the high classification ability.  $P$  value was calculated using the Mann-Whitney  $U$  test. This model was implemented in an app (<https://rserver.h12o.es/EPICOAPP/>, Username: user, password: 0000).



**FIGURE 4.** Density plot. In the X axis, we display the increment of risk probability of critical care necessity for each 1 of the 17 risk factors, according to the syndrome. Patients diagnosed with MIS-C (greenish color) presented the highest probability of needing critical care, followed by bronchopulmonary syndrome (bluish), and gastrointestinal syndrome (yellowish) as compared with mild syndrome (reference). We display the percentual increment of risk for each population depending on the risk factor. The more severe the syndrome, the more the factor increases the risk of critical illness. MIS-C indicates multi-inflammatory syndrome.

group and 21% more risk than in the gastrointestinal syndrome group. Likewise, the presence of comorbidities conferred 6% more risk of critical care in the MIS-C group than in the bronchopulmonary syndrome group and 16% more risk than in gastrointestinal syndrome group. Lymphopenia conferred 6% more risk of critical care in the MIS-C group than in the bronchopulmonary syndrome group and 15% more risk than in the gastrointestinal syndrome group.

By contrast, fever, oxygen saturation or a weight percentile >90 did not confer substantially different risk among the different syndromes.

**DISCUSSION**

In this study, we identified similar risk factors for critical disease as other studies.<sup>8,18</sup> We added several new factors and the syndrome category as a specific risk factor. Remarkably, we show that most different risk factors increase the risk for critical care differently depending on the syndrome: the more severe the syndrome, the more risk the factor confers.

Some risk factors are patient-dependent, such as age and comorbidities. Other identified risk factors suggest immune dysregulation and severe inflammation in critical patients. In the predictive model, we could not use some promising biomarkers such as D-dimer, interleukin-6, or proBNP because they were not consistently measured in patients with mild disease, but those

biomarkers were indeed significantly higher in patients needing critical care. High inflammatory markers as CRP or blood cell disorders, such as leukocytosis, neutrophilia, anemia, lymphopenia, and thrombopenia, were found in severe cases.<sup>19</sup> In our analysis, we found that the best clinical cutoff point for platelets was 220,000/mm<sup>3</sup> instead of 150,000/mm<sup>3</sup>, which is classically used for thrombopenia. The cytopenia found in severe cases suggests either damage to bone marrow or peripheral cells or migration of activated cells to tissues.

We created a novel predictive model to anticipate the probability of critical care. Early recognition of the need for critical care is relevant for starting early treatments. Through a rapid, inexpensive, and comprehensive web app, the attending physician can introduce the patient’s data at admission and the risk of severe disease can be obtained. The evaluation of the algorithm showed significant accuracy and sensitivity. To our knowledge, this is the first model with an online app to help and recognize the need for critical care in children with COVID-19.

**LIMITATIONS**

This study included children who attended in different hospitals, and we focused on those with r-COVID-19. There is a risk of selection, case identification and reporting bias. Access to SARS-CoV-2 testing was not consistent during the enrollment.

The diversity and broadness of the study are, at the same time, strengths, as they provide insight into the disease in a major clinical part of Spain through a prospective collection of data. We used a case record form with several fields shared with other international registries (ISARIC), enabling sharing, but we tailored it specifically for pediatric data collection.<sup>18,20</sup>

Although viral-bacterial coinfection was more frequent in hospitalized children, a full workup for coinfections was not done uniformly, and thus the role of coinfections is not completely clear. The study included few neonates because most neonates with COVID-19 in Spain were included in a different neonatal registry.

The ethnic origin was not recorded, so we cannot compare our study with other studies suggesting worse outcomes in minorities.

Interestingly, some of the factors, such as comorbidity that increased the risk significantly depending on the syndrome, had low relative importance in the model. As this artificial intelligence model is a black box, we cannot assess why this occurred.

This model was built with hospitalized children with r-COVID-19 and should not be applied to outpatients. Finally, the risk predicted by models reflects those of patients receiving care only. The prediction models should be updated regularly because the dynamics of the disease and management strategies may change.<sup>21</sup>

## CONCLUSIONS

Risk factors for severe COVID-19 include inflammation, cytopenia, age, comorbidities, and organ dysfunction. The more severe the syndrome, the more the risk factor increases the risk of critical illness. Risk of severe disease can be predicted with a Bayesian model.

## ACKNOWLEDGMENTS

We thank all the patients and families for their participation in the study and the laboratory staff and clinical staff members who cared for them. Thanks to Kenneth McCreath (Universidad Europea de Madrid) for the style and English revision.

EPICO-AEP Working Group: María de Ceano, Ana Méndez-Echevarría, Talía Sainz, Clara Udaondo, Fernando Baquero (Hospital La Paz), Mar Santos, Marisa Navarro, Elena Rincón, Begoña Santiago, (Hospital Universitario Gregorio Marañón), Pablo Rojo, Daniel Blázquez, Luis Prieto, Elisa Fernández-Cooke, David Torres-Fernández, Ángela Manzanares, Jaime Carrasco, Elena Cobos-Carrasco (Hospital 12 de Octubre), Miguel Lanaspá (Hospital Sant Joan de Déu), Lourdes Calleja (Hospital Niño Jesús), María Espiau, Jacques G. Rivière (Hospital Universitari Vall d'Hebron), Mercedes Herranz (Complejo Hospitalario de Navarra), Fernando Cabañas (Hospital Universitario Quirón salud Madrid), Rut del Valle, María Fernández, Teresa Raga, María de la Serna, Ane Plazaola, Juan Miguel Mesa (Hospital Infanta Sofía), María Dolores Martín (BR Salud), Enrique Otheo, José Luis Vázquez (Hospital Ramón y Cajal), Lola Falcón, Olaf Neth, Peter Olbrich, Walter Goicoechea (Hospital Universitario Virgen del Rocío), Laura Martín (Hospital Universitario Regional de Málaga), Lucía Figueroa (Hospital de Villalba), María Llorente (Hospital Universitario del Sureste), María Penin, Claudia García, María García, Teresa Alvarado (Hospital Príncipe de Asturias), M<sup>a</sup> Inmaculada Olmedo, Agustín López (Hospital Puerta de Hierro), Elvira Cobo (Hospital Fundación Alcorcón), Mariam Tovizi (Hospital del Tajo), Pilar Galán (Hospital Fundación Fuenlabrada), Beatriz Soto, Sara Guillén (Hospital de Getafe), Adriana Navas (Hospital Infanta Leonor) M. Luz García (Hospital de Leganés), Sara

Pérez (Hospital de Torrejón), Amanda Bermejo, Pablo Mendoza (Hospital de Móstoles), Gema Sabrido (Hospital Rey Juan Carlos), María José Hernández (Hospital Central de la Defensa), Ana Belén Jiménez (Fundación Jiménez Díaz), Arantxa Berzosa, José Tomás Ramos (Hospital Clínico San Carlos), Ana López (Hospital Universitari Son Espases), Beatriz Ruiz (Hospital Universitario Reina Sofía), Santiago Alfayate, Ana Menasalvas, Eloisa Cervantes (Hospital Clínico Universitario Virgen de la Arrixaca), María Méndez (Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Ángela Hurtado (Instituto Hispalense de Pediatría), Cristina García, Inés Amich (Hospital San Pedro), Manuel Oltra, Álvaro Villarroya (Hospital Universitari i Politècnic La Fe), Angustias Ocaña (Hospital La Moraleja), Isabel Romero, María Fernanda Guzmán (Hospitales Madrid), M.J. Pascual (Hospital Nisa), María Sánchez-Códez (Hospital Universitario Puerta del Mar), Elena Montesinos (Consorci Hospital General Universitari de València), Julia Jensen, María Rodríguez (Hospital Infanta Cristina), Gloria Caro (Hospital Infanta Elena), Neus Rius, Alba Gómez (Hospital Universitari Sant Joan de Reus), Rafael Bretón (Hospital Clínico Universitario de Valencia), Margarita Rodríguez, Julio Romero (Hospital Universitario Virgen de las Nieves), Ana Campos (Hospital Universitario Sanitas La Zarzuela), Mercedes García (Hospital de Mérida), Rosa María Velasco (Complejo Hospitalario de Toledo), Zulema Lobato (Althaia, Xarxa Assistencial Universitària de Manresa), Fernando Centeno, Elena Pérez (Hospital Universitario Río Hortega), Paula Vidal (Hospital Clínico Universitario Lozano Blesa), Corsino Rey, Ana Vivanco, Maruchi Alonso (Hospital Universitario Central de Asturias), Pedro Alcalá, Javier González de Dios (Hospital General Universitario de Alicante), Eduard Solé, Laura Minguell (Hospital Universitari Arnau de Vilanova), Itziar Astigarraga (Hospital Universitario de Cruces), M<sup>a</sup> Angeles Vázquez, Miguel Sánchez (Hospital Universitario Torrecárdenas), Elena Díaz (Hospital Virgen de la Luz), Eduardo Consuegra (Hospital Universitario de Salamanca), María Cabanillas (Complejo Asistencial Universitario de Palencia), Luis Peña (Hospital Universitario Materno Infantil de las Palmas), Elisa Garrote, Maite Goicoechea (Hospital Universitario de Basurto), Irene Centelles (Hospital General Universitari de Castelló), Santiago Lapeña, Sara Gutiérrez, Soraya Gutiérrez (Complejo Asistencial Universitario de León), Amparo Cavalle (PIUS Hospital de Valls), José María Olmos (Hospital Mare de Déu dels Lliris), Alejandro Cobo, Sara Díaz (Hospital Universitario de Canarias), Beatriz Jiménez (Hospital Universitario Marqués de Valdecilla), Raúl González (Hospital Sant Joan d'Alacant), Miguel Lafuente, Matilde Bustillo (Hospital Infantil de Zaragoza), Natividad Pons, Julia Morata (Hospital Lluís Alcanyis), and Elsa Segura (Hospital Universitario Son Llatzer de Palma de Mallorca), María Bernardino (Universidad Europea de Madrid).

## REFERENCES

1. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis*. 2020;20:689–696.
2. Royal College of Paediatrics and Child Health. RCPCH Research & Evidence team. COVID-19-research evidence summaries. September 25, 2020. Available at: [https://www.rcpch.ac.uk/resources/covid-19-research-evidence-summaries#footnote1\\_Orcmnf](https://www.rcpch.ac.uk/resources/covid-19-research-evidence-summaries#footnote1_Orcmnf). Accessed April 9, 2020.
3. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. *N Engl J Med*. 2020;382:2302–2315.
4. Lavezzo E, Franchin E, Ciavarella C, et al; Imperial College COVID-19 Response Team; Imperial College COVID-19 Response Team. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*. 2020;584:425–429.

5. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. *JAMA Pediatr*. 2021;175:143–156.
6. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis*. 2020;20:911–919.
7. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics*. 2020;145:e20200702.
8. Fernandes DM, Oliveira CR, Guerguis S, et al; Tri-State Pediatric COVID-19 Research Consortium. Severe acute respiratory syndrome coronavirus 2 clinical syndromes and predictors of disease severity in hospitalized children and youth. *J Pediatr*. 2021;230:23–31.e10.
9. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*. 2020;395:1607–1608.
10. Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. *Lancet Rheumatol*. 2020;2:e594–e602.
11. World Health Organ. Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020:1–3. Available at: <https://www.who.int/publications/i/item/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>. Accessed May 15, 2020.
12. Moraleda C, Serna-Pascual M, Soriano-Arandes A, et al. Multi-inflammatory syndrome in children related to SARS-CoV-2 in Spain. *Clin Infect Dis*. 2021;72:e397–e401.
13. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform*. 2009;42:377–381.
14. Training AM. Normal values in children. ACLS Medical Treatment. Available at: <https://aclsmedicaltraining.com/normal-values-in-children/>.
15. Thiele C, Hirschfeld G. Package cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R. Version 1.0.32. 2020. Available at: <http://arxiv.org/abs/2002.09209>. Accessed February 21, 2020.
16. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag; 2016.
17. Goodrich B, Gabry J. *AI& BS. rstanarm: Bayesian Applied Regression Modeling via Stan*. In: R package version 2211. 2020.
18. Swann OV, Holden KA, Turtle L, et al; ISARIC4C Investigators. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. *BMJ*. 2020;370:m3249.
19. Wang S, Fu L, Huang K, Han J, Zhang R, Fu Z. Neutrophil-to-lymphocyte ratio on admission is an independent risk factor for the severity and mortality in patients with coronavirus disease 2019. *J Infect*. 2021;82:e16–e18.
20. Vasconcelos MK, Epalza C, Renk H, Tagarro A, Bielicki JA. Harmonisation preserves research resources. *Lancet Infect Dis*. 2020;3099:30585.
21. Sperrin M, McMillan B. Prediction models for covid-19 outcomes. *BMJ*. 2020;371:1–2.